It is also likely that other factors, such as sex, age, smoking status, PD-L1 expression, CNS or liver metastasis, and EGFR or RAS mutation, influenced the efficacy of anti-PD-1/PD-L1 inhibitors in all trials. The gene discussed is EGFR; the disease is metastasis.